Kim has been in charge of the development of autoimmune disease treatments
ProGen, a new drug development company, announced on Aug. 22 that it has appointed President Kim Jong-kyun as its new CEO.
Since 1994, Kim has been in charge of research and development of innovative new drugs at Yuhan Corporation, serving as the head of the Global New Drug Center and the head of the R&D Strategy Office.
This year, he joined ProGen as president and oversaw the development of autoimmune disease treatments and immuno-cancer drugs. ProGen plans to speed up the development of new drugs led by CEO Kim.
Meanwhile, Dr. Jin Hyun-tak, who has served as CEO, will focus on developing new drugs after resigning as CEO, the company explained.
Kevin Lee 기자
edt@koreapost.com